SAN FRANCISCO — The prevalence of osteonecrosis of the jaw appears to be about 1 in 1,700 for adults taking long-term oral bisphosphonate therapy, according to an initial analysis of a group of Kaiser Permanente Northern California members presented at the annual meeting of the Endocrine Society.
PREVIEW